Cingulate Completes Final FDA Study for CTx-1301 ADHD Treatment
On January 7, 2025, Cingulate Inc. (NASDAQ:CING) announced the successful completion of its final FDA-required study for CTx-1301 (dexmethylphenidate) aimed at treating Attention Deficit Hyperactivity Disorder (ADHD). This study, specifically a food effect study, represents a significant milestone in the development of the drug. The study involved the administration of a single 50mg dose of […]
More Stories
Top 11 E-Commerce Companies in the USA for Your Convenience
There are a huge number of e-commerce companies in the USA. These companies are growing exponentially with the increasing demand....
Strip Law Season 2 Renewed? Check out the Renewal Status
Netflix is cancelling one series after another, and Strip Law, the American adult animated sitcom, is among them. Netflix has...
Netflix’s Upcoming Drama, Husbands in Action, is Releasing Soon
Are you also a Korean drama lover? If yes, Good news! An all-new comedy drama is arriving soon on Netflix....
The Witness, TV Series: Release Date, Cast, Trailer, and Plot
Netflix’s upcoming documentary and television series are based on the real-life murder of Rachel Nickell in 1992. The Witness is...
15+ Famous White Actresses Over 40 Dominating the Film Industry
Want to know about popular white actresses over 40? Here, in this blog, I have mentioned some of the best...
Netflix Has Revealed The Release Date of The Thai Drama, The Evil Lawyer
Thailand’s upcoming courtroom drama, The Evil Lawyer, will be released soon. Netflix has announced the release date. The series features...